Literature DB >> 16080087

Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans.

Luis Ostrosky-Zeichner1, Barbara D Alexander, Daniel H Kett, Jose Vazquez, Peter G Pappas, Fumihiro Saeki, Paul A Ketchum, John Wingard, Robert Schiff, Hiroshi Tamura, Malcolm A Finkelman, John H Rex.   

Abstract

BACKGROUND: Measurement of (1-->3)-beta-D-Glucan (BG) has emerged as an adjunct diagnostic strategy for invasive fungal infections (IFI).
METHODS: Subjects at 6 clinical sites in the United States were enrolled as either fungal infection-negative subjects (n = 170) or subjects with proven or probable IFI according to European Organization for the Research and Treatment of Cancer/Mycoses Study Group criteria (n = 163). A central laboratory and 4 sites performed assays. A single sample was obtained per patient and was evaluated using an assay to detect serum BG derived from fungal cell walls (range, 0 to > 7000 pg/mL).
RESULTS: At a cutoff of 60 pg/mL, the sensitivity and specificity of the assay were 69.9% and 87.1%, respectively, with a positive predictive value (PPV) of 83.8% and a negative predictive value (NPV) of 75.1%. At a cutoff value of 80 pg/mL, the sensitivity and specificity were 64.4% and 92.4%, respectively, with a PPV of 89% and an NPV of 73%. Of the 107 patients with proven candidiasis, 81.3% had positive results at a cutoff value of 60 pg/mL, and 77.6% had positive results at a cutoff value of 80 pg/mL. Of the 10 patients with aspergillosis, 80% had positive results at cutoff values of 60 and 80 pg/mL. The 3 subjects diagnosed with Fusarium species had positive results at a cutoff value of 60 pg/mL. Patients infected with Mucor or Rhizopus species (both of which lack BG) had negative results at both cutoff values, and of the 12 patients with Cryptococcus infection, 3 had positive results at a cutoff value of 60 pg/mL, and 2 had positive results at a cutoff value of 80 pg/mL. Of the subjects with proven positive results who were receiving antifungal therapy (n = 118), 72.9% had results positive for BG at a cutoff value of 60 pg/mL, and 69.5% had results positive for BG at a cutoff value of 80 pg/mL. The interlaboratory sample test r2 was 0.93.
CONCLUSION: Reproducible assay results with high specificity and high PPV in a multicenter setting demonstrate that use of an assay to detect serum BG derived from fungal cell walls is a useful diagnostic adjunct for IFI.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16080087     DOI: 10.1086/432470

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  169 in total

Review 1.  Fungal diagnostics in pneumonia.

Authors:  Erika D Lease; Barbara D Alexander
Journal:  Semin Respir Crit Care Med       Date:  2011-12-13       Impact factor: 3.119

Review 2.  Diagnostic accuracy of serum 1,3-β-D-glucan for pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis.

Authors:  Akira Onishi; Daisuke Sugiyama; Yoshinori Kogata; Jun Saegusa; Takeshi Sugimoto; Seiji Kawano; Akio Morinobu; Kunihiro Nishimura; Shunichi Kumagai
Journal:  J Clin Microbiol       Date:  2011-11-09       Impact factor: 5.948

3.  Post-diagnostic kinetics of the (1 → 3)-β-D-glucan assay in invasive aspergillosis, invasive candidiasis and Pneumocystis jirovecii pneumonia.

Authors:  S Koo; L R Baden; F M Marty
Journal:  Clin Microbiol Infect       Date:  2012-03-08       Impact factor: 8.067

4.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

Review 5.  Candida peritonitis: an update on the latest research and treatments.

Authors:  Herman Anthony Carneiro; Anastasios Mavrakis; Eleftherios Mylonakis
Journal:  World J Surg       Date:  2011-12       Impact factor: 3.352

6.  Serum (1->3)-β-D-glucan measurement in coccidioidomycosis.

Authors:  George R Thompson; Derek J Bays; Suzanne M Johnson; Stuart H Cohen; Demosthenes Pappagianis; Malcolm A Finkelman
Journal:  J Clin Microbiol       Date:  2012-06-12       Impact factor: 5.948

7.  Prospective survey of (1→3)-beta-D-glucan and its relationship to invasive candidiasis in the surgical intensive care unit setting.

Authors:  John F Mohr; Charles Sims; Victor Paetznick; Jose Rodriguez; Malcolm A Finkelman; John H Rex; Luis Ostrosky-Zeichner
Journal:  J Clin Microbiol       Date:  2010-11-03       Impact factor: 5.948

8.  The (1,3){beta}-D-glucan test as an aid to early diagnosis of invasive fungal infections following lung transplantation.

Authors:  Barbara D Alexander; P Brian Smith; R Duane Davis; John R Perfect; L Barth Reller
Journal:  J Clin Microbiol       Date:  2010-08-18       Impact factor: 5.948

Review 9.  [Strategies for antifungal treatment failure in intensive care units].

Authors:  C Arens; M Bernhard; C Koch; A Heininger; D Störzinger; T Hoppe-Tichy; M Hecker; B Grabein; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2015-09       Impact factor: 1.041

Review 10.  [Update: invasive fungal infections: Diagnosis and treatment in surgical intensive care medicine].

Authors:  C Lichtenstern; S Swoboda; M Hirschburger; E Domann; T Hoppe-Tichy; M Winkler; C Lass-Flörl; M A Weigand
Journal:  Anaesthesist       Date:  2010-01       Impact factor: 1.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.